Rituximab as a rescue therapy in patients with glomerulonephritis

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Severe glomerulonephritis (GN) can lead to end-stage kidney disease.
• Conventional treatments for refractory GN are often insufficient.
• Rituximab, an anti-CD20 monoclonal antibody, is explored for its potential in treating autoimmune kidney diseases.

Purpose of the Study:

• To evaluate the efficacy and safety of off-label rituximab in severe refractory GN.
• To assess the impact of rituximab on kidney disease progression over at least one year.
• To analyze treatment outcomes in different categories of GN, particularly Membranous GN (MGN).

Main Methods:

• Multicenter, retrospective study in Saudi Arabia.
• Inclusion of 42 patients with severe refractory GN.
• Assessment of kidney biopsies, proteinuria, and glomerular filtration rate (GFR) before and during follow-up.
• Monitoring of immediate and long-term side effects.

Main Results:

• Within six months, 38% achieved complete remission (CR), 31% partial remission (PR), and 31% no remission.
• The mean follow-up was 19.0 months.
• In Membranous GN (58% of cohort), 40% achieved CR and 28% PR.
• Reported immediate side effects included itching, hypotension, and one case of anaphylaxis.

Conclusions:

• Rituximab appears safe and effective for refractory GN, including Membranous GN.
• The study supports further investigation into rituximab's role in various GN types.
• Larger, prospective studies are recommended to solidify these findings.